ea0022p560 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010
Castro Maria Angeles Bazarra
, Sievers Caroline
, Pozza Susanne Bechtold-Dalla
, Schwarz Hans Peter
, Stalla Gunter Karl
Introduction: Discontinuation of GH therapy in patients with COGHD after attainment of final height has been associated with impaired somatic development, altered peak bone mass and cardiovascular risk factors. A well-managed transition of care between paediatric and adult health services can improve the clinical and social outcomes in adolescents with GHD.Objective: To assess the quality of the transfer between children and adult medical services in our...